R. J. Lindmark

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor

Jeffery A. Zablocki, Masateru Miyano, Robert B. Garland et al. · Journal of Medicinal Chemistry · 1993 · 107 citations

Medicine, Medicinal Chemistry, Pharmacology +17

A highly stereoselective Michael addition to an .alpha.,.beta.-unsaturated ester as the crucial step in the synthesis of a novel .beta.-amino acid-containing fibrinogen receptor antagonist

Joseph G. Rico, R. J. Lindmark, Thomas E. Rogers et al. · The Journal of Organic Chemistry · 1993 · 52 citations

Medicine, Medicinal Chemistry, Pharmacology +7

A novel series of orally active antiplatelet agents

Jeffery A. Zablocki, Foe S. Tjoeng, Philippe R. Bovy et al. · Bioorganic & Medicinal Chemistry · 1995 · 32 citations

Medicine, Medicinal Chemistry, Pharmacology +12

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase

John K. Walker, Shaun R. Selness, Rajesh Devraj et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 21 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents

Philippe R. Bovy, F. S. TJOENG, J. G. RICO et al. · Bioorganic & Medicinal Chemistry · 1994 · 14 citations

Medicine, Medicinal Chemistry, Pharmacology +14